title: Neuroendocrine and clinical effects of transdermal 17 beta-estradiol in postmenopausal women.
abstract: The neuroendocrine and clinical effects of transdermal 17 beta-estradiol (rated at 50 micrograms/day; TTS 50) were studied in 40 postmenopausal women; ten additional postmenopausal women did not receive any drugs. The changes in LH and rectal temperature induced by the infusion of the opioid antagonist naloxone (10 mg i.v. bolus plus 10 mg/h for 4 h) were used to evaluate the central activity of endogenous opioid peptides. TTS 50 increased opioid activity, as evidenced by the restoration of the LH response (P less than 0.01) and the enhancement of the hypothermic effect (P less than 0.05) of naloxone. A greater reduction in hot flushes was observed in TTS 50-treated subjects than in untreated women, with the maximal effect of TTS 50 achieved after 3 months of therapy. TTS 50 did not modify the concentrations of circulating lipids, glucose or liver enzymes but reduced the biochemical parameters indicative of bone reabsorption. Bone density of the distal radius significantly increased during TTS 50 (P less than 0.02), reaching its maximum value after 6 months of therapy. Thereafter bone density declined, but more slowly than in untreated women. Our data suggest that TTS 50 has marked neuroendocrine effects, that it diminishes the incidence of hot flushes and reduces bone demineralization. By contrast, it has a very little, if any, metabolic impact on the liver or on glucose and lipid metabolism.
authors.affiliation: Department of Obstetrics and Gynecology, University of Pisa, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Cagnacci
authors.forename: G B
authors.initials: GB
authors.lastname: Melis
authors.forename: R
authors.initials: R
authors.lastname: Soldani
authors.forename: A M
authors.initials: AM
authors.lastname: Paoletti
authors.forename: M
authors.initials: M
authors.lastname: Gambacciani
authors.forename: A
authors.initials: A
authors.lastname: Spinetti
authors.forename: P
authors.initials: P
authors.lastname: Fioretti
mesh_terms: D000279:Administration, Cutaneous; D000328:Adult; D000469:Alkaline Phosphatase / Q000378:metabolism; D001831:Body Temperature / Q000187:drug effects; D015519:Bone Density / Q000187:drug effects; D002118:Calcium / Q000378:metabolism; D004958:Estradiol / Q000008:administration & dosage* / Q000097:blood; D015914:Estrogen Replacement Therapy; D004970:Estrone / Q000097:blood; D005260:Female; D005483:Flushing; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D008055:Lipids / Q000097:blood; D007986:Luteinizing Hormone / Q000097:blood; D008593:Menopause / Q000378:metabolism; D008875:Middle Aged; D009270:Naloxone / Q000494:pharmacology; D011374:Progesterone / Q000097:blood; D011388:Prolactin / Q000097:blood
chemical_list: D008055:Lipids; D004970:Estrone; D009270:Naloxone; D011374:Progesterone; D004958:Estradiol; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D000469:Alkaline Phosphatase; D002118:Calcium